2 completed, 1 terminated, 1 unknown. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow HER2 Positive: new trials by email Literature Review of HER2 Positive trials Research Report on HER2 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer Pyrotinib Maleate Tablets, Albumin Paclitaxel, Trastuzumab - Breast Cancer, HER2 Positive | Phase 1 / Phase 2 | Unknown | West China Hospital | 20 | 2019-11-01 | 2019-11-05 |
| Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules AZD5363 - Advanced Solid Malignancy, Safety and Tolerability | Phase 1 | Completed | AstraZeneca | 285 | 2010-12-01 | 2025-06-29 |
| Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer Lapatinib and Capecitabine and Vinorelbine - Metastatic Breast Cancer, HER2 Positive | Phase 1 | Terminated | Sponsor GmbH | 12 | 2010-10-01 | 2014-11-21 |
| Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer lapatinib and temozolomide - Metastatic Breast Cancer, Brain Metastases | Phase 1 | Completed | Jules Bordet Institute | 18 | 2008-01-01 | 2012-09-19 |
Breast Neoplasms (4) · Brain Neoplasms (1) · Endometrial Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Ovarian Neoplasms (1) · Uterine Cervical Neoplasms (1)
Breast Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Nervous System Diseases (2) · Adnexal Diseases (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1)
Lapatinib (2) · Capecitabine (1) · Temozolomide (1) · Trastuzumab (1) · Vinorelbine (1) · capivasertib (1)
AstraZeneca (1) · Jules Bordet Institute (1) · Sponsor GmbH (1) · West China Hospital (1)
Belgium (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · Singapore (1) · Spain (1) · United Kingdom (1) · United States (1)
Evandro de Azambuja, MD, PhD (1) · Gaia Schiavon, MSD (1) · Ting Luo, MD (1) · Udai Banerji, MD, PhD (1) · Ulrike Soeling, MD (1)
PMID 29066505, PMID 32312891, PMID 33863913, PMID 34250397, PMID 35242683